In Russia, preclinical studies of the CaTeVac oncology vaccine have been completed, and it is proposed to start its use in 2027, the Office of the Deputy Prime Minister of the Russian Federation reported. The drug is aimed at training the patient's immune system to identify and destroy tumor cells. According to TASS, in the future the product can be used to treat melanoma, kidney cancer, tumors of the central nervous system and other neoplasms when the options of standard treatment have been exhausted.